Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: jayhawk969 who wrote (25567)	9/21/1998 10:33:00 AM
From: Henry Niman	Respond to of 32384

I don't have a copy of the article. It was read to me last week and I thought that it was a very recent BioWorld article. As I recall the article discussed pipelines and financing. Robinson mentioned the long list or LGND products at various stages of development. The products mentioned by name are already in the clinic, and did not represent anything new. The number of compounds winding up pre-clinical testing and getting close to entering the clinic, as well as those that were in earlier pre-clinical development sounded very much like what is listed at home.att.net The only thing new that I heard was a discussion of the value of a Biotech with 3-4 compounds and outstanding shares of 35 million versus a Biotech with 30 some odd products and outstanding shares of 45-60 million. He was talking in general terms about financing vehicles for Biotechs and definitely mentioned a private placement. Although he didn't say that LGND was planning a private placement, that is what I thought when I heard the quote. A reread of the article would probably be worthwhile for me and a close reading would be useful to just about any LGND shareholder. The info is in a written document and if it's not BioWorld, I'm not sure what it was in.